


DIABETES

The Journal of the American Diabetes Association



MAX RUBNER

VOLUME 6, NUMBER 4




JULY-AUGUST 1957

for maximum convenience
and ease of self-injection




B-D DIABETIC EQUIPMENT



The result of careful planning and experience, Diabetic Injection Kit (No. 70) makes self-injection safer and more convenient for your patients. Designed for easy maintenance of sterile equipment, this handy kit contains STERITUBES® for carrying sterilized syringe and needles, vials for cotton and alcohol, and space for two vials of insulin. Case has been designed to accommodate the Busher Automatic Injector.

B-D Insulin Syringes: Individually gauged and certified for accurate dosage—different colors for different scales simplify administration of various strengths of insulin—scale markings fused on the glass for easier reading.

B-D Needles: Assure easy penetration—minimize seepage and afterpain—precision ground for greatest keenness, uniformity and safety.




BECTON, DICKINSON AND COMPANY, RUTHERFORD, N. J.

B-D AND STERITUBE, T. M. REG. U. S. PAT. OFF.



Sweeten Lime Mist with **Sucaryl**[®]

**...you save 128 calories
and you can't taste the difference**



MINTED LIME MIST

2 cups warm water 1½ teaspoons
½ cup fresh lime juice Sucaryl solution
⅛ tsp. mint extract 1 pint dietetic
4 drops green food lime carbonated
coloring beverage

Mix all ingredients except beverage. Chill 3 hours in refrigerator. Add beverage, pour in glasses filled with crushed ice. Garnish with maraschino cherry, wedge of lime, fresh mint. 6 servings.



Warm weather days...invitation to tall, frosty drinks...and extra, unwanted calories! But, here's a tip for weight watchers; sweeten foods and drinks this summer with Sucaryl, and save a lot of calories. This Sucaryl-sweetened Minted Lime Mist,* for instance, has *just 5 calories!* Made with sugar, the same drink would contain 133 calories. More happy news: you can't taste the difference.

*This recipe, plus dozens of others for calorie-saving foods and beverages, is in the new Sucaryl recipe booklet; get your free copy at your neighborhood drugstore.



ABBOTT LABORATORIES • NORTH CHICAGO, ILLINOIS

707180



can you read **this** thermometer,



doctor?

Naturally not. Missing calibration makes it worthless.

Equally useless and dangerous is a "quantitative" urine-sugar test that does not quantitate dependably, or omits readings in the critical range.

Enzyme urine-sugar tests are sensitive and specific for glucose—excellent "yes" or "no" tests but undependable for quantitation. King and Hainline,¹ after testing 1,000 urines, found an enzymatic urine-sugar test unable to distinguish in the important range between ½ per cent and 2 per cent or more of urinary glucose. Leonards,² in a report on 4,020 tests, revealed that "...in 502 out of 804 tests the wrong interpretation was made." He concluded that enzymatic urine-sugar testing "...as a quantitative procedure is unsatisfactory and can lead to serious error in the interpretation of a patient's clinical condition."²

Failure to recognize this limitation of enzyme tests may result in incorrect insulin dosage,² and may lead to diabetic complications.

(1) King, J. W., and Hainline, A., Jr.: Commercial Glucose Oxidase Preparations for the Detection of Glucose in Urine, *Cleveland Clin. Quart.* 23:212, 1956. (2) Leonards, J. R.: Evaluation of Enzyme Tests for Urinary Glucose, *J.A.M.A.* 163:260 (Jan. 26) 1957.

reliable readings throughout the critical range—
does not omit ¾% (++) and 1% (++++)

color
calibrated
CLINITEST[®]
BRAND

a 15 year "standard" in urine-sugar testing



AMES COMPANY, INC. • ELKHART, INDIANA • Ames Company of Canada, Ltd., Toronto

30157

Please mention DIABETES when writing to advertisers.



VOLUME 6, NUMBER 4

CONTENTS

JULY-AUGUST 1957

- THE RESPONSES OF THE SMALLER BLOOD VESSELS AND THE SERUM PROTEINS IN PREGNANT DIABETIC SUBJECTS 307
Jörn Ditzel, M.D., and Pierre Moinat, M.D., Boston
- STUDIES OF ABNORMAL CARBOHYDRATE METABOLISM IN PREGNANCY: THE SIGNIFICANCE OF IMPAIRED GLUCOSE TOLERANCE 324
Hugh L. C. Wilkerson, M.D., and Quentin R. Remein, Boston and Washington, D.C.
- EFFECTS OF AMPHENONE IN PATIENTS WITH DISTURBED CARBOHYDRATE METABOLISM 330
Joseph J. Hoet, M.D., Albert E. Renold, M.D., Roy Hertz, M.D., and George W. Thorn, M.D., Boston
- INTERACTION BETWEEN INSULIN AND ZINC IN THE ISLETS OF LANGERHANS 335
Helmut Maske, M.D., Munich, Germany
- A STUDY OF SERUM LIPOPROTEIN AND CHOLESTEROL DETERMINATIONS IN 901 DIABETICS 342
Alexander D. Lowy, Jr., M.D., and Joseph H. Barach, M.D., with the statistical assistance of Zdenek Hrubec, A.B., Pittsburgh

Continued on page 5

Max Rubner was born in Munich in 1854. When twenty-four he embarked on his classical studies of energy metabolism. In 1885 he became Professor of Hygiene at Marburg and in 1891 occupied the same position at Berlin. In 1909 he became Professor of Physiology at Berlin and remained there till his retirement in 1924.



Among his many contributions were the Isodynamic Law, the Law of Surface Area and the determination of the caloric equivalents of foodstuffs. The cover photograph of Rubner is reproduced from Fielding H. Garrison's History of Medicine, 1929, with the permission of W. B. Saunders Company, Philadelphia, Pennsylvania.

alert your diabetic patients to the danger of acidosis

“...It is just as important...for the [diabetic] patient to be able to detect ketone bodies in the urine as it is to do... [a test for urine-sugar with] *Clinitest*®.”*

ACETEST®
BRAND tablet test for ketonuria

Three simple steps—performed in less than one minute—will alert your patients to the danger of acidosis. Recommend *Acetest* to your diabetics for testing when their urine is strongly positive for sugar or whenever intercurrent illness occurs. It is especially important in pregnant diabetics and in diabetic children.

...and in routine urinalysis *Acetest* aids in early detection of ketosis in gastrointestinal disorders, pregnancy, dehydration, surgical patients and sick children.

Acetest Reagent Tablets, bottles of 100 and 250.

*Coleman, F.: J. Kentucky M. A. 52:769, 1954.



AMES COMPANY, INC • ELKHART, INDIANA

Ames Company of Canada, Ltd., Toronto

02556

Please mention DIABETES when writing to advertisers.



CONTENTS

Continued from page 3

PRELIMINARY STUDIES ON THE DEMONSTRATION OF INSULIN IN THE ISLETS BY THE FLUORESCENT ANTIBODY TECHNIC	354
<i>Paul E. Lacy, M.D., and Jack Davies, M.D., St. Louis</i>	
ENZYMATIC TESTS FOR GLUCOSURIA	358
<i>John J. Moran, M.D., Paul L. Lewis, M.D., John G. Reinhold, Ph.D., and F. D. W. Lukens, M.D., Philadelphia</i>	
EDITORIALS	
<i>The Responses of the Smaller Blood Vessels and the Serum Proteins in Pregnant Diabetic Subjects</i>	363
<i>Irving H. Leopold, M.D., Philadelphia</i>	
<i>Mechanical Factors in the Localization of Atherosclerosis</i>	
<i>Walter M. Bortz, II, M.D., and Edward L. Bortz, M.D., Philadelphia</i>	
<i>Idiopathic Hypoglycemia in Children and Central Nervous System Damage</i>	
<i>Edmund C. Burke, M.D., Rochester, Minnesota</i>	
MAX RUBNER	369
<i>Harvey C. Knowles, Jr., M.D., Cincinnati</i>	
CORRESPONDENCE	371
BOOK REVIEWS	373
ABSTRACTS	375
ORGANIZATION SECTION	385
<i>The Seventeenth Annual Meeting * Sixth Post- graduate Course * Eighteenth Annual Meeting * 1956-57 Medical Student-Intern Essay Contest Awards * 1957-58 Medical Student-Intern Essay Con- test * 1958 Lilly Award * Research Fellowships * Third IDF Congress * Diabetes Week, 1957 * Student Subscription Rates * New Members</i>	
NEWS OF AFFILIATE ASSOCIATIONS	389
NEWS NOTES	390

DIABETES

The Journal of the American Diabetes Association

EDITOR, WILLIAM C. STADIE, M.D., *Philadelphia* • ASSOCIATE EDITOR, IRVING GRAEF, M.D., *New York*
ABSTRACTS EDITOR, WILLIAM R. KIRTLEY, M.D., *Indianapolis* • MANAGING EDITOR, EDWARD W. SANDERSON, *New York*
ART EDITOR, W. I. VAN DER POEL, *New York*

EDITORIAL BOARD

CHAIRMAN, CHARLES H. BEST, M.D., <i>Toronto</i>	VICE CHAIRMAN, FRANK N. ALLAN, M.D., <i>Boston</i>
EDWARD L. BORTZ, M.D., <i>Philadelphia</i>	FRANKLIN B. PECK, SR., M.D., <i>Indianapolis</i>
ARTHUR R. COLWELL, SR., M.D., <i>Chicago</i>	HERBERT POLLACK, M.D., <i>New York</i>
GARFIELD G. DUNCAN, M.D., <i>Philadelphia</i>	HENRY T. RICKETTS, M.D., <i>Chicago</i>
GEORGE M. GUEST, M.D., <i>Cincinnati</i>	RANDALL G. SPRAGUE, M.D., <i>Rochester, Minn.</i>
HARVEY C. KNOWLES, JR., M.D., <i>Cincinnati</i>	WALLACE M. YATER, M.D., <i>Washington, D.C.</i>
	MAX MILLER, M.D., <i>Cleveland</i>

CONSULTING FOREIGN EDITORS

GEORG R. CONSTAM, M.D., *Zurich, Switzerland*; B. A. HOUSSAY, M.D., *Buenos Aires, Argentina*;
H. C. HAGEDORN, M.D., *Gentofte, Denmark*; R. D. LAWRENCE, M.D., *London, England*

ABSTRACTORS

RAUL D. ALFARO, M.D., <i>Indianapolis</i>	JOSEPH L. IZZO, M.D., <i>Rochester, N. Y.</i>	LEON S. SMELO, M.D., <i>Birmingham, Ala.</i>
DONALD I. BELL, M.D., <i>Evanston, Ill.</i>	ROBERT L. JACKSON, M.D., <i>Columbia, Mo.</i>	WILLIAM J. STEENROD, JR., M.D., <i>Seattle</i>
RICHARD C. CULLEN, M.D., <i>Denver</i>	BERT F. KELTZ, M.D., <i>Oklahoma City</i>	JOHN W. STEPHENS, M.D., <i>Portland, Ore.</i>
MARTIN G. GOLDNER, M.D., <i>New York</i>	CHARLES A. ROSENBERG, M.D., <i>Memphis</i>	ELEANOR A. WASKOW, M.D., <i>Phoenix</i>
GEORGE J. HAMWI, M.D., <i>Columbus, Ohio</i>	ROBERT W. SCHNEIDER, M.D., <i>Salem, Ore.</i>	GERALD A. WRENSHALL, PH.D., <i>Toronto</i>

DIABETES is published by the American Diabetes Association, Inc., to provide an official Journal for the Association and to furnish the medical profession with information concerning diabetes and related fields of medicine.

Contributions are invited from practicing physicians, clinical and laboratory investigators, and others who have data of importance to offer in these fields. Manuscripts, if suitable, will be accepted providing that the text has not been printed elsewhere.

Matter appearing in DIABETES is copyrighted. Permission to reproduce all or part of papers appearing in it may be granted on application, under appropriate conditions and if proper credit is given.

Papers presented at the Annual Meeting of the American Diabetes Association become the property of the Association,

and the manuscripts must be submitted to the Secretary at the time of the Meeting. At the discretion of the Editorial Board, they may be published in full, in part, or by abstract only. If only an abstract is used, permission may be granted on request from the authors to publish elsewhere.

Manuscript Specifications: Manuscripts should be typewritten, with double spacing and, if possible, submitted in duplicate. References should be presented in the style illustrated by the following examples:

For Periodicals—Banting, F. G., and Best, C. H.: The internal secretion of the pancreas. *J. Lab. & Clin. Med.* 7:251-66, Feb. 1922.

For Books—Allen, Frederick M.: Studies Concerning Glycosuria and Diabetes. Cambridge, Harvard University Press, 1913, p. 461.

An abstract or summary of the content of the paper in not more than 250 words should usually appear at the end. If possible, this should be self-contained and understandable without reference to the text.

Photographs, drawings and figures should be suitable for reproduction purposes. Photographs should be unmounted, untrimmed glossy prints. The names of authors should appear on the back. The top of photographs and figures should be indicated.

Galley proofs are sent to the principal author of each paper, with a price list and order blank for reprints.

All manuscripts and editorial correspondence should be addressed to the Editorial Office, DIABETES, American Diabetes Association, Inc., 1 East 45th Street, New York 17, New York.

Subscription and Advertising Information

DIABETES, The Journal of the American Diabetes Association, is published every other month by the Association at 1 East 45th Street, New York 17, New York. Registered cable address: "DIABETES NEW YORK." Entire contents copyright 1957 by the American Diabetes Association, Inc.; all rights reserved. Entered as second-class matter at the post office, New York, New York, under the Act of March 3, 1879, as amended.

Members receive the Journal as part of their

membership privileges. The annual subscription rates for nonmembers are as follows: United States, U. S. Possessions, Canada and the Pan-American Union, \$9.00 per year; elsewhere, \$10.00 per year. Individual copies available at \$2.00 each.

Medical Students, Interns and Residents: \$4.50 per year.

Correspondence concerning subscriptions should be addressed to the Subscription Department,

DIABETES. Checks, money orders and drafts for subscriptions should be made payable to the American Diabetes Association, Inc., and sent to the aforementioned address.

All inquiries about advertising and other business matters should be addressed to the Executive Director of the American Diabetes Association. The publishers reserve in their full discretion the right to accept or reject any proposed advertising and the right to cancel any advertising contract.

HANSON SCALES

for controlled diets

Rotating dial eliminates computation as each item of food is added to serving plate.

Used by hospitals, doctors, dietitians, and patients. The standard scale of the medical profession. Complies with Federal Specifications AAA-S-110.

"Available through all medical supply houses"



MODEL 1411
Capacity 500 grams by 2 grams. Stainless Steel platform, white enamel body, easy to keep clean. Has glass protected dial.

Price \$16.50

MODEL 1440
Same as No. 1411 but without glass dial cover. Enamel dial is rotated by knob.

Price \$11.50



Weighmaster Bath Scale

Avoid the complication of added weight. Hold your weight to your doctor's recommendation with a HANSON bath scale. The finest in personal weight scales. Triple tested for lasting accuracy. Power View magnifying glass.

Deluxe All Chrome Finish

\$10.95

HANSON SCALE CO. (Est. 1888)
Northbrook, Illinois

sugar-sweet

and free of
metallic aftertaste



For those who can take little or no sugar, the pure sweet taste of 'Saxin' remains unaltered even in cooking and baking. A sample will be sent on request.

Supplied in bottles of 200 and 1,000

 Burroughs Wellcome & Co. (U.S.A.) Inc., Tuckahoe, N.Y.

TARGET

DIABETES

be sure... be tested




DIABETES WEEK / NOV. 17-23

JULY-AUGUST, 1957

Please mention DIABETES when writing to advertisers.

MANY CELLU DIET FOODS TO ASSIST YOU

 ... when prescribing
your patients' diets



Now you have a choice of three types of CELLU tree-ripened fruits.

1. New CELLU Artificially Sweetened Fruit. Packed with calcium cyclamate for those who prefer the flavor of sweetened cooked fruit.
2. CELLU Juice-Pak Fruit. Unsweetened and packed in its own natural juice. Food value equal to fresh fruit.
3. CELLU Water-Pak Fruits. Unsweetened and packed in water. Food value approximately one-third lower than fresh fruit.

WRITE FOR SPECIAL INTRODUCTORY OFFER.



**CHICAGO DIETETIC
SUPPLY HOUSE, INC.**

Dept. 3-1, Chicago 12, Illinois

DINE WELL WITH CELLU FOODS!

A-7

Orinase Prescription Information

Dosage: Patients responsive to Orinase may begin therapy as follows:

First day
3 Gm. 

Second day
2 Gm. 

Third day
1 Gm. 

Usual maintenance dose 1 Gm.
(must be adjusted to patient's response)

To change from insulin to Orinase:

If previous insulin dosage was less than 40 u./day . . . reduce insulin 30% to 50% immediately; gradually reduce insulin dose if response to Orinase is observed.

more than 40 u./day . . . reduce insulin 20% immediately; carefully reduce insulin beyond this point if response to Orinase is observed. In these patients, hospitalization should be considered during the transition period.

Caution: During the initial "test" period (not more than 5 to 7 days), the patient should test his urine for sugar and ketone bodies three times daily and report to his physician daily. For the first month, he should report at least once weekly for physical examination, blood sugar determination, and white cell count (with differential count, if indicated). After the first month, the patient should be seen at least once a month, and the above studies carried out.

It is especially important that the patient, because of the simplicity and ease of administration of Orinase, does not develop a careless attitude ("cheating" on his diet, for example) which may result in serious consequences and failure of treatment.

Supplied: In 0.5 Gm. scored tablets, bottles of 50.

Complete literature available on request.

Upjohn

THE UPJOHN COMPANY
KALAMAZOO, MICHIGAN



now available...

←
save

Please mention DIABETES when writing to advertisers.

Upjohn

the new **oral** hypoglycemic agent

ORINASE*

(Tolbutamide, Upjohn)

Employed in more than 18,000 patients during the clinical investigation

Ready for your prescription now. Orinase is now available in all leading prescription pharmacies. But please, before you prescribe this new drug, be sure you understand its limitations.

Indications. Orinase is most likely to benefit the patient in whom the diabetes is relatively mild and stable, is not adequately controlled by dietary restrictions alone, and developed sometime after the age of 30 years.

Contraindications. Orinase is contraindicated in patients with 1) diabetes of the type known variously as juvenile, growth-onset, unstable, or brittle; 2) a history of diabetic coma; 3) diabetes complicated by ketosis, acidosis, coma, fever, severe trauma, gangrene, Raynaud's disease, or serious impairment of renal or thyroid function; 4) hepatic dysfunction; and 5) diabetes adequately controlled by dietary restriction.

Effects. In patients with a satisfactory response to Orinase, the blood sugar falls, glycosuria diminishes, and such symptoms as pruritus, polyuria, and polyphagia disappear. It is *not* a substitute for insulin. And it requires the same adherence to basic principles of diabetes control as does insulin, e.g., dietary regulation; tests for

glycosuria and ketonuria; hygiene; exercise; instruction of the patient to recognize and counteract impending hypoglycemia, to follow rigidly directions regarding diet and continuing use of the drug and to report immediately to the physician any feeling of illness. Extreme care must be taken during the transition period to avoid ketosis, acidosis, and coma.

Side effects. Hypoglycemia may occur occasionally during the transition period from insulin to Orinase. Other untoward reactions to Orinase are uncommon, usually of a nonserious nature, and tend to disappear on adjustment of dosage, e.g., gastrointestinal disturbances, headache, variable allergic skin manifestations, and alcohol intolerance.

Clinical toxicity. Aside from an occasional hypoglycemia, Orinase appears to be remarkably free of gross clinical toxicity. There is no evidence of crystalluria or other untoward effects on renal function, or of hepatotoxicity. Except for a rare *leukopenia of mild degree, which has been reversible (in some instances, even under continued therapy)*, there have been no adverse effects on hematopoietic function.

*TRADEMARK, REG. U.S. PAT. OFF.

Please mention DIABETES when writing to advertisers.

Third of a series

The metabolic advantages of Levugen®

(Fructose, Mead Johnson)

in diabetes




"...an ideal vehicle for the parenteral administration of water in diabetic acidosis..."
 "...preferable to glucose as a parenteral sugar for diabetics without acidosis."¹

less hyperglycemia*
Mg./100 cc.

better utilization*
Pyruvate
Mg./100 cc.

less glycosuria*



Miller and associates² observed that Levugen, in sharp contrast to intravenous glucose, was well utilized by diabetic patients and produced less hyperglycemia and glycosuria. This was confirmed by Peters¹ who recognized that fructose avoids the undesirable features of glucose administration such as hyperglycemia, polyuria and salt depletion.

Moderate amounts of Levugen do not appreciably raise blood sugar or upset water balance but do provide utilizable carbohydrate. Since Levugen does not require insulin to enter the metabolic cycle, it is uniquely suited for use in the early hours of diabetic acidosis.

In diabetics without acidosis Levugen spares protein wastage and prevents ketosis without provoking hyperglycemia and consequent fluid balance disturbances.¹

1. Peters, J. P.: Some Remarks on Diabetic Acidosis, *Yale J. Biol. & Med.* 27:152 (Dec.) 1954.

2. Miller, M., et al.: Metabolism of Intravenous Fructose and Glucose in Normal and Diabetic Subjects, *J. Clin. Invest.* 31:115 (Jan.) 1952.

*Adapted from Miller et al²

MEAD JOHNSON
SYMBOL OF SERVICE IN MEDICINE

Please mention DIABETES when writing to advertisers.



There's Always

Something Good

in the

ADA FORECAST

Factual information about diabetes, warnings against quackery and nostrums, new recipes and menus, inspirational articles by diabetics who live well-adjusted lives, and practical suggestions for meeting the problems of day-to-day living appear in each issue of the FORECAST, the magazine for diabetics and their families published bimonthly by the American Diabetes Association, Inc.




Be sure your diabetic patients know about the FORECAST. They will be better patients if they read this magazine, for they can rely on its authoritative information.

Order your reception room copy now—and recommend that your diabetic patients subscribe.

Only \$2.00 per year, \$3.50 for two years, \$4.75 for three years. Add 25¢ per year for subscriptions outside the United States, its possessions and Canada. Write to the ADA FORECAST, American Diabetes Association, Inc., 1 East 45th St., New York 17, N. Y.

Sample copies and subscription forms will be sent promptly on request.

Please mention DIABETES when writing to advertisers.



the 60-second urine glucose test

TES-TAPE

(Urine Sugar Analysis Paper, Lilly)

**specific for glucose • adequately
quantitative for clinical use**

'Tes-Tape' is both qualitative and quantitative. Its selective action prevents false positive reactions; assures clinical accuracy. Patients also welcome the convenience, simplicity, and accuracy of 'Tes-Tape.'

The handy plastic dispenser allows you to carry 'Tes-Tape' in your house-call bag for on-the-spot determinations.

*Available at pharmacies
everywhere.*

ELI LILLY AND COMPANY • INDIANAPOLIS 6, INDIANA, U. S. A.

Please mention DIABETES when writing to advertisers.

728035